July 23, 2026 -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China (NMPA) for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement-inhibitor-naïve. This is Haisco's fifth innovative drug approved for marketing and represents an important advance in the treat

July 22, 2026 -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA ha

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biologywithout the need for calcium and vitamin D supplements, with a favorable safety and tolerability prof

July 20, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody) in patients with advanced non-small cell lung cancer (NSCLC). The study will explore the therapeutic potential of this combination, with a particular emphasi

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies,

This Tamgiblimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Sotevtamab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Lesabelimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio

ThalassaX Therapeutics United States Ltd today announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295, a next-generation brain-penetrant Aurora B Kinase selective inhibitor independently discovered and developed using the company's core AI-powered + Chemogenomic technology platform. This study is an open-label, dose-escalation Phase I clinical trial in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmac